Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Quantum Pharma launches Mucodis Rectal Gel
Mucositis is a condition characterised by pain and inflammation of the body's mucous membranes which line the digestive system from the mouth to the anus. Of the circa
Mucositis is a condition characterised by pain and inflammation of the body's mucous membranes which line the digestive system from the mouth to the anus. Of the circa
As previously disclosed, in January 2016 Novartis informed GenVec that enrollment in the trial had been paused in accordance with criteria in the trial's protocol. In April 2016,
The Bill & Melinda Gates Foundation led the financing with an $8M investment followed by $2M each from existing investors Merck, Lilly Asia Ventures and ARCH Venture Partners. The proceeds
The ULTRA study will evaluate the effects of ubenimex in patients with secondary lymphedema of the lower limb(s) who are optimized on physical therapies. Physical therapies, such as
All Series A investors contributed to the financing extension, including Alexandria Venture Investments, Bay City Capital LLC, Lundbeckfond Ventures, New Enterprise Associates (NEA), and Pfizer Venture Investments. Together
The Onivyde, which is also known as nal-IRI or MM-398, in combination with 5-fluorouracil (5-FU) and leucovorin (LV), has been recommended, for the treatment of metastatic adenocarcinoma of
“We are very pleased to announce this important regulatory milestone,” said Alan H. Auerbach, Chief Executive Officer and President of Puma. “Although the use of trastuzumab in the
Following FDA approval, Citron Pharma immediately commenced shipments of the generic version of CRESTOR to its customers in the U.S. Ashok Mayya, Chief Operating Officer, noted, “Our team was
The data obtained in these studies capture the outcomes from its latest R&D efforts demonstrating that Synaffix platform technologies, GlycoConnect and HydraSpace, generate ADCs with significantly improved therapeutic index
The ongoing studies were designed to explore the efficacy and safety of Odefsey among virologically suppressed adult patients switching from the tenofovir disoproxil fumarate (TDF)-based regimens Complera (emtricitabine 200mg/rilpivirine